Sugi Predict

Sugi Predict / Compounds / SCHEMBL1491364

SCHEMBL1491364

SCHEMBL1491364

CNc1ccc(F)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 4/20 0.57
▸ MEN1 O00255 4/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ MAPT P10636 3/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ RAPGEF4 Q8WZA2 1/20 0.55
▸ TSHR P16473 2/20 0.53
▸ SLC2A1 P11166 1/20 0.52
▸ NPC1 O15118 4/20 0.51
▸ RAB9A P51151 4/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ LMNA P02545 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.49
▸ PLA2G1B P04054 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31453595 0.98 HTT (0.55) HTTMEN1KMT2AMAPTALDH1A1
Hydrochloric Acid SCHEMBL18226389 0.98 HTT (0.55) HTTMEN1KMT2AMAPTALDH1A1
Hydrochloric Acid SCHEMBL30475333 0.84 HTT (0.50) HTTMEN1KMT2AMAPTALDH1A1
SCHEMBL2093509 0.82 RAPGEF4 (0.55) HTTMEN1KMT2AMAPTALDH1A1
SCHEMBL31757629 0.82 RAPGEF4 (0.55) HTTMEN1KMT2AMAPTALDH1A1
SCHEMBL14491938 0.80 SLC2A1 (0.68) HTTMEN1KMT2AMAPTALDH1A1
SCHEMBL30667273 0.78 EPHX1 (0.52) HTTMEN1KMT2AMAPTALDH1A1
SCHEMBL856883 0.78 EPHX1 (0.52) HTTMEN1KMT2AMAPTALDH1A1
SCHEMBL31099069 0.78 RAPGEF4 (0.50) HTTMEN1KMT2AMAPTALDH1A1
SCHEMBL1421215 0.78 RAPGEF4 (0.50) HTTMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110218206-B Bisindolylmaleimide derivative and preparation method and application thereof 中国海洋大学 2022-03-04 — — CN claimed
CN-110526903-B Bisindolylmaleimide derivative and preparation method and application thereof 中国海洋大学 2021-12-10 — — CN claimed
EP-4688775-A1 SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE Avelos Therapeutics Inc. (KR) 2026-02-11 — — EP disclosed
EP-4598901-A1 PYRROLIDINE AND IMIDAZOLIDINE BASED DNA POLYMERASE THETA INHIBITORS AND USE THEREOF Thomas Jefferson University (US) 2025-08-13 — — EP disclosed
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer ARTIOS PHARMA LIMITED (GB) 2025-07-15 — — US disclosed
CN-114302874-B Indole carboxamide derivatives and pharmaceutical compositions containing the same 国际药品株式会社 2025-02-25 — — CN disclosed
WO-2025016138-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) 2025-01-23 — — WO disclosed
CN-119255992-A Heterocyclic derivatives, compositions and uses thereof 北京丹擎医药科技有限公司 2025-01-03 — — CN disclosed
CN-114667167-B Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-12-20 — — CN disclosed
WO-2024205311-A1 SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE AVELOS THERAPEUTICS INC. (KR) 2024-10-03 — — WO disclosed
WO-2024191988-A1 3,4-FUSED BICYCLIC PYRROLIDINE AND 3,4-FUSED BICYCLIC PYRROLIDINONE COMPOUNDS CYTEIR THERAPEUTICS, INC. (US) 2024-09-19 — — WO disclosed
WO-2004103998-A1 QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-02 — — WO disclosed
CN-1496364-A Substituted quinazoline derivatives and their use as inhibitors — 2004-05-12 — — CN disclosed
US-20030187002-A1 Substituted quinazoline derivatives and their use as inhibitors ASTRAZENECA AB (SE) 2003-10-02 — — US disclosed
EP-1299381-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS AstraZeneca AB (SE) 2003-04-09 — — EP disclosed
WO-2002000649-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS ASTRAZENECA AB (SE) 2002-01-03 — — WO disclosed
US-4360465-A PLANT GROWTH REGULATORS BASF AKTIENGESELLSCHAFT (DE) 1982-11-23 — — US disclosed
EP-0017946-B1 SALTS OF ALPHA-AMINOACETANILIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PLANT GROWTH REGULATORS BASF Aktiengesellschaft (DE) 1982-04-14 — — EP disclosed
US-4257805-A Herbicidal (4-substituted-phenylamino)-3-(trifluoromethyl)phenyl)ureas SHELL OIL COMPANY (US) 1981-03-24 — — US disclosed
EP-0017946-A1 Salts of alpha-aminoacetanilides, process for their preparation and their use as plant growth regulators BASF Aktiengesellschaft (DE) 1980-10-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187002-A1 Substituted quinazoline derivatives and their use as inhibitors AURKA, AURKC, AURKB HTT 4535/4885MEN1 2422/4885KMT2A 790/4885
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer SDHA, DPYD, TP53 HTT 1520/4885MEN1 1074/4885KMT2A 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.